– USA, MA – Pyxis Oncology, an immuno-oncology company focused on developing a new family of antibody-based immunotherapies derived from novel insights into the biology of the tumor microenvironment, today announced the appointment of Lara Sullivan, M.D. as CEO and Director. She succeeds Longwood General Partner and founding CEO, David Steinberg, who assumes the role of Chairman of the Board of Directors while John Flavin, the founding Chairman, will remain on the Board as an Independent Director.
“We are excited to welcome Lara to Pyxis, and look forward to her leadership as we build and advance our pipeline. Lara brings a remarkable range of skills and experience spanning drug development, corporate strategy, finance and business development to the role of CEO at Pyxis,” said David Steinberg, Chairman, Pyxis Oncology.
“In addition, I would like to thank our co-founder and outgoing Chairman John Flavin for his exceptional early leadership and pivotal role in conceptualizing and establishing Pyxis. We look forward to his ongoing engagement and further contributions as an Independent Director,” he added.
About Lara Sullivan
Prior to joining Pyxis, Lara was Founder and President of SpringWorks Therapeutics where she conceived of and executed the clinical-stage spin-out from Pfizer and raised the Series A. In her executive roles at Pfizer, she led early-stage R&D portfolio operations and strategy, and developed novel business models for early-stage financing. Previously, Lara was an Associate Partner at McKinsey & Co. and a Principal at Paul Capital Partners, and earlier in her career worked in healthcare finance at CS First Boston. She is an Independent Director of Rexahn Pharmaceuticals.
“This is a very exciting time in immuno-oncology and Pyxis has a unique platform to understand the tumor microenvironment that will enable the company to make major contributions to the field,” said Lara. “I am looking forward to working closely with our scientific co-founders and the Pyxis scientific team to unlock new avenues to restore the potency of dysfunctional immune cells. Building off this solid foundation with the support of our investors, I believe Pyxis will be able to make a real difference in the lives of cancer patients as we move our antibody programs into the clinic.”
Lara holds an M.D. from the University of Pennsylvania School of Medicine, an MBA from The Wharton School at the University of Pennsylvania, and a B.A. in Comparative Literature from Cornell University.
About Pyxis Oncology
Pyxis Oncology is an immuno-oncology company focused on developing novel therapies to help patients defeat difficult to treat cancers. Built on the ground-breaking research of Pyxis co-founder and Scientific Advisory Board Chair, Dr. Thomas Gajewski, Pyxis is pursuing promising novel targets derived from the latest insights into the tumor microenvironment. Pyxis has generated preclinical data on these targets and is developing a pipeline of novel antibodies with the potential to help new patient populations not currently served by today’s immunotherapies.
For more information: https://www.pyxisoncology.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.